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Peptide immunotherapy for childhood
allergy - addressing translational challenges
Karen J Mackenzie1,2, Stephen M Anderton1,3 and Jürgen Schwarze1,2*
Abstract
Allergic sensitisation usually begins early in life. The number of allergens a patient is sensitised to can increase over
time and the development of additional allergic conditions is increasingly recognised. Targeting allergic disease in
childhood is thus likely to be the most efficacious means of reducing the overall burden of allergic disease. Specific
immunotherapy involves administering protein allergen to tolerise allergen reactive CD4+ T cells, thought key in
driving allergic responses. Yet specific immunotherapy risks allergic reactions including anaphylaxis as a
consequence of preformed allergen-specific IgE antibodies binding to the protein, subsequent cross-linking and
mast cell degranulation. CD4+ T cells direct their responses to short “immunodominant” peptides within the
allergen. Such peptides can be given therapeutically to induce T cell tolerance without facilitating IgE cross-linking.
Peptide immunotherapy (PIT) offers attractive treatment potential for allergic disease. However, PIT has not yet
been shown to be effective in children. This review discusses the immunological mechanisms implicated in PIT and
briefly covers outcomes from adult PIT trials. This provides a context for discussion of the challenges for the
application of PIT, both generally and more specifically in relation to children.
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Introduction
Allergic disease including atopic eczema, allergic rhinitis,
allergic asthma and food allergy causes significant
patient morbidity and economic costs to healthcare sys-
tems [1,2]. Current clinical management primarily relies
on allergen avoidance, treating symptoms as they arise
(often using medications such as b2 agonist inhalers,
antihistamines and adrenaline) and generalised suppres-
sion of immune responses (e.g. using corticosteroids).
Therapeutic blockade of cytokines such as interleukin-5
(IL-5) and of IgE have had varied clinical results and
such approaches are reserved for highly selected patient
groups at present [3-5]. Many allergic patients will first
experience symptoms during childhood [6] and allergic
sensitisation may begin very early in infancy, even pre-
natally [7,8]. Children with atopy are at risk of develop-
ing new sensitisations and additional allergic conditions
as they get older [1,9]. Identifying atopic children early
and modifying disease progression is therefore a hugely
attractive therapeutic goal [10].
Evidence suggests a key role for CD4+ T cells, particu-
larly the T helper (Th) 2 subset, in allergy. These cells
express the transcription factor GATA-binding protein
3 (GATA-3) and can produce allergy-associated cyto-
kines such as IL-4, IL-5 and IL-13 which are implicated
in a host of allergic responses such as eosinophil recruit-
ment and airway hyperreactivity [reviewed in [11]]. Th2
cells also provide B cells with help, driving immunoglo-
bulin class-switching towards allergen-specific IgE [11].
Less commonly, and often in concert with Th2 cells,
other helper subsets such as Th1, Th17 and Th9 cells
have also been implicated in the pathogenesis of allergic
asthma in some patients [reviewed in [12]]. Therapeutic
targeting of allergen-reactive CD4+ T cells therefore has
the capacity to abrogate downstream allergic responses
[11]. One way of doing this is through specific immu-
notherapy (SIT) which targets CD4+ T cells via the
administration of protein allergen. First used over a cen-
tury ago [13], much of SIT’s therapeutic effects have
been shown to result from the induction of tolerance of
allergen-reactive CD4+ T cells so they no longer mount
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an allergic response to the allergen. This can occur
either through direct effects on allergen-reactive T cells
and/or through the actions of T regulatory cells [14].
SIT can significantly improve symptoms in allergic
patients [15], therapeutic effects can be long-lasting [16]
and SIT for allergic rhinitis may reduce the likelihood of
future asthma development [reviewed in [17]]. Yet SIT
can also be risky. Pre-existing allergen-specific IgE can
bind to multiple sites on protein allergen, leading to IgE
cross-linking on mast cells, inducing mast cell degranu-
lation and subsequent allergic reactions, even anaphy-
laxis [18-20].
Such SIT-associated risks can be overcome by identi-
fying short peptides from within the protein allergen to
which the CD4+ T cell response is directed [10]. Such
“immunodominant” peptides can bind efficiently to
major histocompatibility complex II (MHC II) to induce
T cell responses and can therefore be used to generate
T cell tolerance, while their short length and lack of ter-
tiary conformational structure do not facilitate IgE
cross-linking [21]. Such therapeutic application of pep-
tides [hereafter referred to as peptide immunotherapy
(PIT)] was first developed in rodent autoimmune dis-
ease models [22]. However, clinical translation of PIT
has been faster for allergy than for autoimmune disease
[10]. The early manifestation and often progressive
nature of allergic disease means that maximising PIT’s
disease-modifying potential would require targeting
allergic children (Figure 1). However, clinical trials of
PIT have so far not included children and the need for
scrupulous safety concerning novel paediatric
treatments necessitates further understanding of the
mechanisms involved in successful PIT.
Immunological mechanisms of PIT
PIT harnesses the body’s capacity to induce peripheral T
cell tolerance. This capacity is paramount to prevent
inflammatory responses both to harmless exogenous
antigens and to self antigens [23]. Lack of pathogen-
associated or inflammation-associated “danger signals”
in such circumstances promote a tolerogenic rather
than an inflammatory response. Hence, administering a
soluble peptide in the absence of danger signals (e.g. in
the absence of lipolysaccharide (LPS) and/or an adju-
vant) can induce tolerance, whereas administration of
the same peptide with an adjuvant promotes an inflam-
matory/immunogenic response [21]. Soluble peptides
administered by intranasal, oral, intravenous, subcuta-
neous and intradermal routes all have the potential to
induce tolerance [24-27].
Dendritic cells
In order to elicit a T cell response, peptide must be pre-
sented to T cells by antigen presenting cells in the con-
text of MHC II, facilitating engagement of the T cell
receptor (TCR). Dendritic cells (DCs), antigen present-
ing cells optimally able to stimulate T cells, are strongly
implicated in driving tolerance. CD11c-deficient mice
(lacking conventional DCs, plasmacytoid DCs and Lan-
gerhans cells) develop spontaneous autoimmunity,
implicating DCs in the maintenance of peripheral
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Figure 1 Proposed model of the effects of PIT on disease progression in children with severe atopy. Evidence suggests that in
susceptible individuals, allergic sensitisation begins early in life, even prenatally, preceding development of allergic conditions such as eczema.
The number of allergens an individual is sensitised to and the number of diagnosed allergic conditions can increase with age. Inducing
tolerance to an allergen using PIT early, rather than later, in life has the potential to reduce sensitisation to additional allergens and reduce the
risk of progression to multiple allergic conditions particularly for children with severe atopy.
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tolerance [28]. Peptide is rapidly presented on DCs after
therapeutic administration [29]. It appears that the acti-
vation status of the DC is the prime orchestrator of
whether or not a T cell becomes tolerant since “imma-
ture” DCs expressing low levels of costimulatory mole-
cules have been found to induce T cell tolerance, in
contrast to activated DCs [25,30]. Considering that differ-
ent DC subtypes may be tissue-specific with particular
anti-inflammatory or pro-inflammatory characteristics
[31], the nature of DC-T cell interactions, and hence the
mechanism of tolerance induction, could vary with differ-
ent PIT delivery routes.
T cells and the 3 Pillars of Tolerance
The strength of the TCR signal induced by a peptide
can affect the outcome of PIT. Peptides with strong
MHC II avidity form a stable peptide-MHC II interac-
tion, hence generate a strong TCR signal and have an
improved ability to induce tolerance [32]. This may be
due to a resultant rapid, and synchronous T cell
response [33]. Studies, predominantly in mice, have
shown that the induction of T cell tolerance is likely to
be effected by three fundamental mechanisms - deletion,
adaptation and regulation [34]. All have variably been
thought to contribute to the effects of PIT [25-27,35,36],
however, certain mechanisms may be more therapeuti-
cally desirable than others.
Deletion
PIT can lead to targeted deletion of CD4+ T cells [25].
This mechanism is advantageous in that deletion
removes the possibility of such cells reverting to patho-
genicity in the future. High dose PIT and/or induction
of a strong but transient TCR signal appear to favour
deletion [25,37].
Adaptation
T cells can also be rendered tolerant through anergy - a
state of unresponsiveness. A particular form of T cell
anergy, known as adaptive tolerance, may be most rele-
vant in vivo [38]. Adaptive tolerance is associated with
inhibition of proliferation and cytokine production and
has been demonstrated, to varying degrees, to occur
after PIT in several murine and human studies
[35,36,39-41]. One drawback is that adaptive tolerance is
not necessarily permanent, and persistence of the pep-
tide may be required to maintain tolerance [39]. Hence,
adaptive tolerance alone may be insufficient to maintain
long-term therapeutic effects after a short course of
treatment.
Regulation
Several subsets of T regulatory cells capable of con-
straining immune responses have been described
[reviewed in [42]]. Generating regulatory T cells using
PIT is therapeutically desirable because of the potential
for long-lived suppression of unwanted allergic
responses. Using PIT to induce allergen-reactive T
regulatory cells also has the potential to down-regulate
responses to other allergens. This “bystander suppres-
sion” [10] could be particularly beneficial in the allergic
lung where multiple potential allergens are continually
encountered, and because allergic lung inflammation has
been found to increase the likelihood of developing
allergic sensitisation to additional aeroallergens [43].
Different T regulatory cell subsets vary in their
mechanism(s) of action and whether or not they express
the transcription factor Foxp3. In fact, there are limited
data concerning the ability of PIT to induce Foxp3+ T
regulatory cells. That said, peptide-reactive Foxp3+ T
regulatory cells were generated in a model using a pep-
tide complex designed to specifically target peptide to
DCs, ensuring peptide uptake and presentation [44].
Interestingly, generation of Foxp3+ T regulatory cells
was reduced using high dose peptide or when peptide
was presented by activated DCs [44].
One means whereby T regulatory cells often effect
regulation is via production of immunosuppressive cyto-
kines such as IL-10. In beekeepers, the frequency of IL-
10 producing allergen-reactive T cells has been found to
increase following tolerance induction to bee venom,
which develops naturally in response to multiple bee
stings [45]. Some murine studies of PIT have clearly
demonstrated peptide-reactive T regulatory cells as the
source of IL-10 following PIT [26]. IL-10 was also impli-
cated in the therapeutic effects of PIT in a mouse model
of allergic airways disease [35]. In one clinical study, IL-
10 production increased from allergen-reactive T cells
after PIT [36] and, in another, CD4+ T cells obtained
from patients after PIT had suppressive activity in vitro
[40]. It appears that the development of regulatory
mechanisms following PIT may be favoured by regimens
using repeated peptide dosing [26], however the optimal
dosage and delivery regimes favouring regulation remain
unclear.
Overall, therapeutic targeting of allergen-reactive
(principally Th2) CD4+ T cells using PIT could, there-
fore, occur via deletion, adaptation, or regulation, or
most probably a combination of these, echoing the var-
ied mechanisms attributed previously to clinical effec-
tiveness following SIT [[46,47] and reviewed in [14]]. By
targeting allergen-specific CD4+ T cells, and conse-
quently modulating the provision of B cell help, PIT has
also been found to be capable of beneficially altering
allergen-specific antibody levels in some studies [[35]
and discussed in [48]]. While deletion or adaptation of
allergen-reactive Th2 cells should reduce allergic
responses to that particular allergen (in part because
reductions in Th2 cytokine production should inhibit
the recruitment of innate immune cells such as eosino-
phils), the induction of regulatory mechanisms also con-
fers the potential to suppress allergic responses to a
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variety of other allergens and is thus particularly advan-
tageous. Existing data from limited human studies of
PIT and from experimental murine PIT models (dis-
cussed above) indicate that the mechanism of tolerance
induction that predominates following PIT is likely to
be influenced by factors such as the nature of disease,
the dose of peptide and the delivery route (Figure 2).
PIT in adult allergy trials
Since the first clinical PIT trial in adult allergic patients
in the 1990s [49] significant advances have been made,
but as yet there are no PIT studies involving children.
The majority of clinical PIT studies have utilised pep-
tides from the major cat allergen Fel d 1. The outcomes
from these trials have been comprehensively reviewed
previously [24] and will therefore not be covered in
detail here. Briefly, however, initial trials used two 27
amino acid immunodominant Fel d 1 peptides. In those
studies, short term improvements in lung function tests
and improvements in clinical symptoms were described
to a variable extent [49-52]. More recently, there has
been a move towards using shorter peptides, typically
15-17 amino acids in length. For Fel d 1, these were
administered in the form of multiple, overlapping pep-
tides encompassing the majority of the Fel d 1 protein.
This has the advantage of maximising the number of
allergen-reactive T cells that may be tolerised since
patients may respond to multiple immunodominant
peptides and immunodominant peptides may vary
between individuals with different HLA types. Using
Deletion Adaptive Tolerance Regulation
Peptide
“Immature”
DC”
Peptide 
reactive T 
cell
High dose of peptide
Peptide generating 
strong but transient 
TCR signal
Persistence 
of peptide
Multi-dose PIT
Low dose of 
peptide
Tolerant T cells may 
revert to pathogenicity
Lack of on-going 
regulatory effects to 
further control other 
potentially 
pathogenic T cells
Disadvantages
Potential for regulation 
of allergic responses 
to additional allergens 
(bystander 
suppression)
Loss of effector T cell 
proliferation and 
cytokine production
Permanent removal 
of pathogenic T 
cells
Advantages
Figure 2 Possible impact of the mode of peptide delivery on the mechanisms of T cell tolerance. The nature of peptide delivery may
influence the mechanism(s) of tolerance that are evoked. High dose peptide or peptides that lead to strong, transient TCR stimulation may
favour deletion of allergen-reactive T cells. Persistence of peptide may favour adaptive tolerance and thus anergy/unresponsiveness of allergen-
reactive T cells. Adaptive tolerance may, however, be reversed when peptide no longer persists. Regulatory mechanisms may be favoured by
multi-dose regimens and/or low dose applications.
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shorter peptides also abrogated the risk of allergen-spe-
cific IgE binding which had occasionally been reported
in studies using longer peptides [50]. This approach
using multiple short, overlapping peptides reduced late-
phase skin reactions to cat allergen, reduced prolifera-
tion of peripheral blood mononuclear cells (PBMC) to
cat allergen and improved symptoms in some patients
[53,54]. In one study, PBMC responses to Fel d 1 pep-
tides not included in the treatment vaccine were also
reduced, implying linked-suppression, whereby tolerance
induced to one peptide inhibits responses to other pep-
tides within the same protein [35].
PIT also offers a potentially safer approach to aller-
gen-specific immunotherapy for bee venom allergy,
where SIT has a high frequency of severe allergic reac-
tions [55]. PIT using peptides from the phospholipase
A2 bee venom allergen has led to reduced T cell prolif-
eration to those peptides and altered cytokine profiles e.
g. by increasing IL-10, in some studies [36,56,57]. PIT
has also been found to reduce the severity of allergic
responses to deliberate bee stings [56].
PIT can therefore improve clinical outcomes in aller-
gic patients in some instances. Furthermore, although
PIT studies have so far focused on aeroallergens or
venom allergies, future application of PIT for the treat-
ment of food allergies is also a possibility, particularly
given the continued identification of food allergen
derived T cell epitopes [58]. It is, however, apparent
from clinical studies so far that the effects of PIT can be
variable and therapeutic effects are not necessarily seen
across all clinical readouts. These inconsistencies are
likely due in part to inter-trial variability of factors such
as clinical readouts, PIT regimens, nature of disease and
whether patients have received immunotherapy pre-
viously, which can complicate the assessment of clinical
effectiveness.
Difficulties with PIT
Does PIT remove the risk of anaphylaxis
associated with SIT?
The need to avoid severe IgE-driven hypersensitivity
reactions, including anaphylaxis, is the primary reason
why PIT rather than SIT may be more applicable to
treating allergic children. Crucially, anaphylaxis and
other severe hypersensitivity reactions are extremely
rare after PIT. However, a PIT trial involving multiple
sclerosis (MS) patients was halted due to a number of
hypersensitivity reactions [59]. The peptide used con-
tained sequence alterations designed to improve its ther-
apeutic effects [an altered peptide ligand (APL), further
discussed below]. Interestingly, it was levels of IgG1 and
not IgE which were elevated in patients displaying
hypersensitivity reactions [59]. This potential for genera-
tion of anaphylaxis-promoting peptide-specific IgG1
should be noted, although importantly this has not been
reported in PIT allergy studies.
Long-term disease exacerbation
To our knowledge, there are no reports of PIT inducing
long-term exacerbation of allergic disease. However, a
phase II PIT trial using an APL in MS patients was dis-
continued due to disease exacerbations [60]. The APL
displayed low immunogenicity and good tolerogenic
potential in vitro yet seemed to promote an inflamma-
tory T cell response in some patients. Exacerbation of
disease has also been noted to occur using an unaltered
peptide in a murine allergy model [61]. These rare
examples highlight that there is a small risk that peptide
administration may induce an inflammatory instead of a
tolerogenic response in some circumstances, illustrating
the need for incisive understanding of the mechanisms
involved in PIT.
Late Asthmatic Reactions
PIT has induced late asthmatic reactions (LARs) in
some patients during Fel d 1 allergy trials. LARs resulted
in reduced lung function occurring at 2-3 hours follow-
ing treatment and peaking at around 6 hours [62]. LARs
were not associated with immediate hypersensitivity
reactions/anaphylaxis. It appears that patients with cer-
tain HLA types are more likely to experience a LAR,
although HLA type alone is not predictive of LAR devel-
opment [63]. These MHC associations and the timing of
LARs point to a T cell mediated mechanism implying
that in some patients, cytokines produced by T cells
responding to peptide can mediate airway hyperrespon-
siveness. Crucially, induction of LARs is not required in
order to induce T cell tolerance [53] and LARs can be
managed by careful regimen planning. In patients who
have developed a LAR with PIT, repeating treatment
within 2 to 8 weeks using the same dose of peptide
induces T cell tolerance without promoting further
LARs [53].
Challenges of applying PIT to a diverse population,
with particular regard to children
HLA variation CD4+ T cells recognise peptide in the
context of MHC II and TCR specificity for a peptide is
a function of the peptide itself and the MHC II it is pre-
sented on. The polygenicity and polymorphic nature of
the human leucocyte antigen (HLA) region means that
there is extensive variation in the MHC II molecules
expressed by different individuals. Most allergens will
contain multiple peptide epitopes which can vary in
their ability to bind to different MHC II molecules [64],
meaning that there will be differences in the allergen-
derived peptides which are recognised by different
patients’ T cells. This poses difficulties for identifying
immunodominant peptides capable of inducing toler-
ance in a HLA-diverse patient population [10]. HLA
class II allele associations have been described for
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allergic diseases [65], yet the complex nature of allergy
means that, with the exception of coeliac disease [66],
these associations are weaker than for many autoim-
mune diseases [67]. Although technically possible to
characterise immunodominant peptides on an individual
patient basis, this approach is unlikely to be feasible
both in terms of cost and practicality [68]. But HLA
diversity does not preclude the application of PIT to a
diverse population [68]. Peptides exhibit considerable
promiscuity in their ability to bind to MHC II mole-
cules. A single peptide may bind to MHC II molecules
derived from multiple HLA loci [e.g. HLA-DP, -DQ and
-DR [69]], and/or to multiple alleles of an HLA mole-
cule [(e.g. HLA-DR1 and HLA-DR53) [70]]. Addition-
ally, use of multiple, overlapping allergen-derived
peptides increases the likelihood that a PIT vaccine will
contain peptides recognised by a range of HLA-dispa-
rate individuals. These characteristics, together with the
fact that some HLA types are more common than
others, means that a strategic selection of a small num-
ber of allergenic peptides could be used to treat a wide
range of patients.
Nature of the peptide There are advantages to altering
the sequence of a therapeutic peptide. APLs have
defined amino acid substitutions which can change
MHC and/or TCR binding properties of the peptide
[21]. Different alterations can modulate the T cell
response elicited by the peptide e.g. APLs that instead
of inducing an allergy-associated Th2 T cell response,
generate a Th1 response. The latter induces cytokines
such as interferon-g (IFN-g) which can sometimes
antagonise allergic responses [71] and has been found
to be expressed by an increased frequency of CD4+
cells in some PIT studies [72]. The stimulatory capa-
city of a peptide can also be modulated. A “superago-
nist” APL has an increased ability to stimulate a T cell
response whereas an “antagonist” APL can inhibit T
cell activation, even in the presence of an agonist.
Antagonists have obvious therapeutic applications and
have been shown capable of preventing disease in ani-
mal models [73,74]. There is concern, however, that an
APL defined as an antagonist from its effect in vitro
on T cells with a limited TCR repertoire may behave
differently in vivo on encountering a more diverse T
cell repertoire [75]. Using APL antagonists therefore
risks unpredictable effects, borne out by the aforemen-
tioned MS trial [60].
Other applications of APLs could be more amenable
to clinical translation. For example, APLs can be gener-
ated to reduce the allergenicity of a peptide. Leech et al
altered a myelin-based peptide reducing its IgG1 binding
affinity while maintaining its tolerising capacity [76].
Hence, whilst antagonist APLs may not have widespread
application, the potential to alter peptides to improve
tolerogenicity or reduce allergenicity should not be
dismissed.
Route The most desirable route of delivery of PIT for
children would be oral or intranasal as they are mini-
mally distressing. PIT delivered in these ways can be
effective in inducing tolerance [32,77], raising hope that
these routes may be applicable to the treatment of aller-
gic children in future. It is also possible that a sublingual
approach, which has been used to deliver SIT [78], may
also prove applicable to PIT. At present however, most
allergy-based clinical studies focus on subcutaneous or
intradermal PIT administration.
Dose and Regimen There remains no clear consensus
as to the optimal peptide dose or regimen which have
varied considerably in different trials [49-51,79]. Dose-
escalation is advantageous because it is less likely to
cause adverse effects and, if side effects such as a LAR
develop following a particular dosage, withholding
dosage increase until LAR is no longer provoked can
be effective [79]. Different regimens may induce differ-
ent tolerogenic mechanisms. For example, high dose
regimens may be more likely to promote a deletional
mechanism of tolerance [25] whereas lower dose or
multi-dose regimens may provoke induction of IL-10
producing cells capable of regulation [26,35]. Hence,
low dose, incremental regimens may be more attrac-
tive therapeutically because of the potential for pro-
duction of regulatory T cells which could exert their
effects on pathogenic T cells reactive to other
allergens.
A key question is how long PIT needs to be given to
induce long-term tolerance? Limited data on this exist
from PIT allergy studies which to date have focused on
short-term clinical outcomes. However, tolerance fol-
lowing SIT has been demonstrated up to 7 years after
completion of treatment [80]. Although these studies
involve initial up-dosing followed by maintenance dos-
ing for around 3 years, the frequency and duration of
maintenance dosing necessary for long-term tolerance
remains undefined. For PIT it is probable that a mainte-
nance regimen will be required to generate long-term
tolerance. Ideally such a regimen would be infrequent to
encourage compliance, particularly for children. Addi-
tionally, maintenance dosage will need to be determined.
A high maintenance dose may risk adverse events, parti-
cularly if a child has missed a previous dose. Indeed, a
review of near fatal reactions to SIT found the majority
occurred during maintenance and not during up-dosing
[81]. It would be ideal if a low, infrequent maintenance
dose was capable of preserving long-term tolerance.
Concurrent illness Concurrent illness may hold particu-
lar relevance for application of PIT to children. Data
concerning this do not exist for PIT. However, giving
SIT during concurrent systemic illness has been
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associated with fatalities [20] and current guidelines
advise against giving SIT during an acute systemic ill-
ness [82]. It may be that giving SIT during a period of
systemic inflammation can precipitate an inflammatory
response and exacerbate disease. It would therefore be
advisable to apply these conditions to the use of PIT.
There is, however, a lack of data concerning immu-
notherapy and concurrent viral infection. Children
experience a higher frequency of viral infections than
adults. Such infections may not cause systemic illness or
fever but may still locally activate immune cells such as
DCs [83]. Peptide presented to T cells by DCs which
have been activated by a viral infection theoretically
risks incurring an inflammatory response rather than a
tolerant one. Interestingly, in a murine allergic airways
model, concurrent influenza infection prevented toler-
ance induced by intranasal SIT and enhanced allergic
inflammation of the airways [84]. In a different study,
allergen exposure via the airways at the time of viral
infection induced allergen-specific IgG1 and subse-
quently led to anaphylaxis upon allergen re-exposure
[85]. Clearly, these examples may only represent the
effects of exposure to whole protein allergen, not pep-
tide, during severe, systemic viral infection. It is thus
important to address whether a variety of viral infec-
tions, particularly mild non-systemic ones, have any det-
rimental impact on the outcome of PIT.
Conclusions
PIT holds promise for the treatment and modification of
allergic disease. There have been significant advances in
the application of PIT to adult allergic patients, and
there is substantial scope for future opportunities for
the application of PIT. Yet to maximise therapeutic effi-
cacy necessitates translation to allergic children. For
this, further understanding of the underlying mechan-
isms involved in PIT, potential confounding factors such
as viral infection and the interplay between dose, regi-
men and route need to be further elucidated. Mechanis-
tic studies utilising experimental models together with
carefully structured, appropriately powered clinical trials
looking at a host of outcome measures should aid future
translation to the paediatric clinic.
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